Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xcorporeal reduces workforce by 73%
The company has streamlined its operations through a series of initiatives designed to reduce annual expenses by approximately $3.5 million to a current operating burn rate of approximately
The company has streamlined its operations through a series of initiatives designed to reduce annual expenses by approximately $3.5 million to a current operating burn rate of approximately
The consideration comprises of $3 million paid in cash to PHC at closing and additional payments totaling $2 million that are contingent upon Pivotal Research Group achieving certain
According to Cordis, Nevo is the first and only drug-eluting stent utilizing a unique reservoir technology, which Cordis acquired from Conor Medsystems in 2007, and incorporates hundreds of
As the company’s chief science officer/chief medical officer, Mr Chew will establish a unified medical voice for Sanofi-Aventis US among internal and external stakeholders. Mr Chew will be
A randomized, double-blind, placebo-controlled, three-way cross-over study was conducted in 108 seasonal allergic rhinitis (SAR) patients to compare the relative efficacy of Captisol-Enabled budesonide + azelastine nasal spray
Bovie Medical, a manufacturer and marketer of electrosurgical products, has reported a net income of $38,767, or nil per diluted share, for the fourth quarter of 2008, compared
The resulting average blood levels exceeded those that have been shown in third party studies using injectable parathyroid hormone (PTH) to stimulate bone growth in osteoporotic women. No
The randomized, multi-center, international Star trial is designed to compare the effects of Zenvia 30/10mg, Zenvia 20/10mg and placebo on involuntary crying/laughing episodes rates. The Star trial had
CytRx, a clinical-stage biopharmaceutical company, has reported a net loss of $27.05m, or $0.30 per share, for the year ended December 31, 2008, compared to a net loss
The lawsuit was filed in response to an abbreviated new drug applications (ANDA) filed by Barr seeking the FDA approval to market and sell generic versions of Shire’s